Designation of Para-Aminosalicylic Acid (Paser) as an orphan drug - Link Medical Products Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring their quality, safety and efficacy. One of the key issues the Act addresses is the availability of treatments for rare and life-threatening conditions, often referred to as orphan diseases, which typically do not attract significant investment from the pharmaceutical industry due to their limited market potential. In response to this gap, the Therapeutic Goods Administration (TGA) has the authority to designate certain drugs as orphan drugs, thereby providing incentives to manufacturers to develop treatments for these conditions. On 11 February 2015, Dr. Anthony Gill, Delegate of the Secretary, designated para-aminosalicylic acid (PASER) as an orphan drug for the treatment of multi-drug resistant tuberculosis, thereby recognising the need to support the development of treatments for this rare and serious condition. The policy objective is to encourage the research, development, and availability of therapeutic goods for conditions that affect a small number of people in Australia.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia's Department of Health, applies to the designation of therapeutic goods, including medications, within Australia. This Act and its associated regulations, such as the Therapeutic Goods Regulations 1990, provide a framework for the regulation of therapeutic goods to ensure their safety, quality, and efficacy. Specifically, the designation of para-aminosalicylic acid (PASER) as an orphan drug under this legislation pertains to its use as part of combination therapy for the treatment of multi-drug resistant tuberculosis. This designation recognises the importance of developing treatments for rare diseases and conditions where there is limited commercial incentive. The Act applies to the sponsor of the drug, in this instance, Link Medical Products Pty Limited, and the enteric coated granules dose form of PASER. The geographic reach of this legislation is national, applying across all states and territories of Australia, ensuring a consistent regulatory approach to therapeutic goods. The orphan drug designation can lead to various incentives and support for the development and availability of such medications, but specific details on these incentives are not provided in the text. The Act may extend or restrict its application through subordinate instruments, such as further regulations or guidelines issued by the TGA.

Key Provisions

The main operative section of the legislation, under the Therapeutic Goods Act 1989, pertains to the designation of para-aminosalicylic acid (PASER) as an orphan drug. Specifically, section 16J of the Therapeutic Goods Regulations 1990 provides the framework for this designation. Under this provision, Dr Anthony Gill, acting as the Delegate of the Secretary, has designated PASER as an orphan drug on 11 February 2015. This designation is specifically for the use of PASER in the treatment of multi-drug resistant tuberculosis, and it specifies that the drug must be used as part of an appropriate combination therapy. The designated dose form for this indication is enteric coated granules. The obligations imposed by this legislation on the parties involved are primarily related to the designation and use of PASER as an orphan drug. The sponsor of PASER, in this case, Link Medical Products Pty Limited, must ensure that the drug is used according to the specified indication and dose form. The sponsor is also responsible for any further requirements or obligations as outlined under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. Furthermore, the designation itself implies certain obligations, such as ensuring that the drug is available for the treatment of the specified condition and that any claims made about its efficacy and safety are substantiated. There are no explicit offences, penalties, or civil/criminal consequences mentioned in the provided text. However, the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 generally include provisions for enforcement actions against breaches of the Act. These can include fines, imprisonment, and other civil or administrative penalties for non-compliance. The specific penalties would depend on the nature and severity of the breach, and would be in accordance with the provisions of the Act and any applicable regulations. In this particular context, failure to comply with the designated use of PASER as an orphan drug could potentially lead to enforcement actions under the broader framework of the Therapeutic Goods Act 1989.